Wheaton Precious Metals Bolsa (NYSE: WPM)

Últimas noticias sobre Wheaton Precious Metals (NYSE:WPM) Bolsa

Wheaton Precious Metals

Wheaton Precious Metals Corp is a precious metal streaming company. The company metal streaming company which generates its revenue primarily from the sale of precious metals (gold, silver and palladium) and cobalt. Its reportable segment includes: Gold, Silver, Palladium, Platinum, Cobalt, and Other.

Wheaton Precious Metals Corp Common Shares (Canada)

Wheaton Precious Metals Corp

WESTERN PACIFIC MNRLS LTD by Western Pacific Minerals Ltd.

Western Pacific Minerals

STEVEN LAUB, Board Member at Rambus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBS#NASDAQ">RMBS</a>), executed a substantial insider sell on May 20, according to an SEC filing.
What Happened: A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000917273/000091727325000082//Archives/edgar/data/917273/000091727325000082/0000917273-25-000082-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday outlined that LAUB executed a sale of 3,653 shares of Rambus with a total value of $202,960.
Tracking the Wednesday's morning session, Rambus shares are trading at $55.5, showing a down of 0.27%.
<h3>All You Need to Know About Rambus</h3>
Rambus Inc is a semiconductor solutions provider offering high-speed, high-security computer chips and Silicon intellectual property. The company's key products include memory interface chips, built for high speed and efficiency; silicon IP, providing high-speed memory and chip-to-chip connection technology; and architecture licenses, which allow customers to use portions of Rambus' patented inventions for their own digital electronics. The firm receives the majority of its revenue from the United States, Taiwan, Asia, Japan, and Singapore.
<h3>Rambus: Delving into Financials</h3>
Revenue Growth: Rambus's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 41.4%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.
Insights into Profitability:
<ul>
<li>
Gross Margin: The company sets a benchmark with a high gross margin of 80.29%, reflecting superior cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Rambus's EPS is below the industry average. The company faced challenges with a current EPS of 0.56. This suggests a potential decline in earnings.
</li>
</ul>
Debt Management: Rambus's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.03.
Evaluating Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 29.14 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 9.99 is above industry norms, reflecting an elevated valuation for Rambus's stock and potential overvaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Indicated by a lower-than-industry-average EV/EBITDA ratio of 19.88, the company suggests a potential undervaluation, which might be advantageous for value-focused investors.
</li>
</ul>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Uncovering the Importance of Insider Activity</h3>
In the complex landscape of investment decisions, investors should approach insider transactions as part of a comprehensive analysis, considering various elements.
Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
<h3>Exploring Key Transaction Codes</h3>
In the domain of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their focus to those taking place in the open market, as meticulously outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000917273">Check Out The Full List Of Rambus's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Insider Trades

Trading Ideas

RMBS

Board Member At Rambus Sells $202K Of Stock

Almir Ambeskovic, CEO at Tripadvisor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIP#NASDAQ">TRIP</a>), disclosed an insider sell on May 20, according to a recent SEC filing.
What Happened: Ambeskovic opted to sell 16,643 shares of Tripadvisor, according to a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001526520/000112760225015074//Archives/edgar/data/1526520/000112760225015074/0001127602-25-015074-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday. The transaction's total worth stands at $255,064.
Tracking the Wednesday's morning session, Tripadvisor shares are trading at $14.25, showing a down of 2.46%.
<h3>Discovering Tripadvisor: A Closer Look</h3>
Tripadvisor is the world's leading travel metasearch company. Its platform offers 1 billion reviews and information on several million accommodations, restaurants, experiences, airlines, and cruises. In 2024, 52% of revenue came from the company's core Brand Tripadvisor segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 46% of sales in 2024, and TheFork, its dining brand, represented 10% of revenue (about 8% of sales were intersegment, which are eliminated from consolidated revenue).
<h3>Understanding the Numbers: Tripadvisor's Finances</h3>
Revenue Growth: Tripadvisor's remarkable performance in 3 months is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 0.76%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Communication Services sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Profitability Metrics:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 93.22%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Tripadvisor's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of -0.08.
</li>
</ul>
Debt Management: With a high debt-to-equity ratio of 1.97, Tripadvisor faces challenges in effectively managing its debt levels, indicating potential financial strain.
Valuation Analysis:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 37.46 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 1.16 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With a below-average EV/EBITDA ratio of 8.57, Tripadvisor presents an opportunity for value investors. This lower valuation may attract investors seeking undervalued opportunities.
</li>
</ul>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Understanding the Significance of Insider Transactions</h3>
Emphasizing the importance of a comprehensive approach, considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Cracking Transaction Codes</h3>
Taking a closer look at transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, meticulously cataloged in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A signifies a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001526520">Check Out The Full List Of Tripadvisor's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TRIP

Tripadvisor CEO Trades $255K In Company Stock

Piper Sandler analyst Justin Crowley assumes CF Bankshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFBK#NASDAQ">CFBK</a>) with a Overweight rating and announces Price Target of $29.

Price Target

Initiation

Analyst Ratings

CFBK

Piper Sandler Assumes CF Bankshares at Overweight, Announces Price Target of $29

Jason Wilder, Chief Operating Officer at Rush Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUSHA#NASDAQ">RUSHA</a>), executed a substantial insider sell on May 20, according to an SEC filing.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0001012019/000143774925017879//Archives/edgar/data/1012019/000143774925017879/0001437749-25-017879-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday showed that Wilder sold 1,231 shares of Rush Enterprises. The total transaction amounted to $69,182. 
Rush Enterprises shares are trading down 0.0% at $51.59 at the time of this writing on Wednesday morning.
<h3>Get to Know Rush Enterprises Better</h3>
Rush Enterprises Inc is a full-service, integrated retailer of commercial vehicles and related services. The company operates in a single segment; Truck Segment includes the operation of a network of commercial vehicle dealerships under the name Rush Truck Centers. It sells commercial vehicles manufactured by Peterbilt, International, Hino, Ford, Isuzu, IC Bus, and Blue Bird and also provides one-stop service for the needs of commercial vehicle customers, including retail sales of new and used commercial vehicles, aftermarket parts sales, service and repair facilities, financing, leasing and rental, and insurance products. The company's business is concentrated in the United States and Ontario, Canada commercial vehicle markets and related aftermarkets.
<h3>Financial Milestones: Rush Enterprises's Journey</h3>
Revenue Challenges: Rush Enterprises's revenue growth over 3 months faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately -1.13%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: The company shows a low gross margin of 19.33%, suggesting potential challenges in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Rush Enterprises's EPS is below the industry average. The company faced challenges with a current EPS of 0.76. This suggests a potential decline in earnings.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 0.8, Rush Enterprises adopts a prudent financial strategy, indicating a balanced approach to debt management.
Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 14.45 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: The Price to Sales ratio is 0.54, which is lower than the industry average. This suggests a possible undervaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): At 8.08, Rush Enterprises's EV/EBITDA ratio reflects a below-par valuation compared to industry averages signalling undervaluation
</li>
</ul>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Unmasking the Significance of Insider Transactions</h3>
While insider transactions should not be the sole basis for making investment decisions, they can play a significant role in an investor's decision-making process.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>A Deep Dive into Insider Transaction Codes</h3>
Taking a closer look at transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, meticulously cataloged in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A signifies a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001012019">Check Out The Full List Of Rush Enterprises's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RUSHA

Chief Operating Officer Of Rush Enterprises Sold $69K In Stock

Making a noteworthy insider sell on May 20, Michael L Goldstone, SVP at Rush Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUSHA#NASDAQ">RUSHA</a>), is reported in the latest SEC filing.
What Happened: Goldstone's recent Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001012019/000143774925017881//Archives/edgar/data/1012019/000143774925017881/0001437749-25-017881-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday unveiled the sale of 4,500 shares of Rush Enterprises. The total transaction value is $234,450.
Rush Enterprises shares are trading down 0.0% at $51.59 at the time of this writing on Wednesday morning.
<h3>Delving into Rush Enterprises's Background</h3>
Rush Enterprises Inc is a full-service, integrated retailer of commercial vehicles and related services. The company operates in a single segment; Truck Segment includes the operation of a network of commercial vehicle dealerships under the name Rush Truck Centers. It sells commercial vehicles manufactured by Peterbilt, International, Hino, Ford, Isuzu, IC Bus, and Blue Bird and also provides one-stop service for the needs of commercial vehicle customers, including retail sales of new and used commercial vehicles, aftermarket parts sales, service and repair facilities, financing, leasing and rental, and insurance products. The company's business is concentrated in the United States and Ontario, Canada commercial vehicle markets and related aftermarkets.
<h3>Breaking Down Rush Enterprises's Financial Performance</h3>
Decline in Revenue: Over the 3 months period, Rush Enterprises faced challenges, resulting in a decline of approximately -1.13% in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.
Profitability Metrics:
<ul>
<li>
Gross Margin: With a low gross margin of 19.33%, the company exhibits below-average profitability, signaling potential struggles in cost efficiency compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Rush Enterprises's EPS lags behind the industry average, indicating concerns and potential challenges with a current EPS of 0.76.
</li>
</ul>
Debt Management: Rush Enterprises's debt-to-equity ratio is below the industry average. With a ratio of 0.8, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Valuation Metrics: A Closer Look
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 14.45 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: With a lower-than-average P/S ratio of 0.54, the stock presents an attractive valuation, potentially signaling a buying opportunity for investors interested in sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Rush Enterprises's EV/EBITDA ratio at 8.08 suggests potential undervaluation, falling below industry averages.
</li>
</ul>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Relevance of Insider Transactions</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision. 
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>Understanding Crucial Transaction Codes</h3>
When it comes to transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S indicates a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001012019">Check Out The Full List Of Rush Enterprises's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Sell Alert: Michael L Goldstone Cashes Out $234K In Rush Enterprises Stock

A substantial insider activity was disclosed on May 20, as III, Board Member at Medpace Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>), reported the exercise of a large sell of company stock options.
What Happened: A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001668397/000166839725000071//Archives/edgar/data/1668397/000166839725000071/0001668397-25-000071-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday revealed that III, Board Member at Medpace Hldgs in the Health Care sector, exercised stock options for 0 shares of MEDP stock. The exercise price of the options was $0.0 per share.
As of Wednesday morning, Medpace Hldgs shares are down by 3.26%, with a current price of $296.62. This implies that III's 0 shares have a value of $0.
<h3>Unveiling the Story Behind Medpace Hldgs</h3>
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical-device firms. It also offers ancillary services such as bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati and its operations are principally based in the US, but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
<h3>Understanding the Numbers: Medpace Hldgs's Finances</h3>
Revenue Growth: Medpace Hldgs's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 9.3%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Evaluating Earnings Performance:
<ul>
<li>
Gross Margin: The company faces challenges with a low gross margin of 31.93%, suggesting potential difficulties in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Medpace Hldgs's EPS outshines the industry average, indicating a strong bottom-line trend with a current EPS of 3.77.
</li>
</ul>
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.21.
Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: Medpace Hldgs's P/E ratio of 23.41 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: The Price to Sales ratio is 4.52, which is lower than the industry average. This suggests a possible undervaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Medpace Hldgs's EV/EBITDA ratio at 17.5 suggests potential undervaluation, falling below industry averages.
</li>
</ul>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Important</h3>
While insider transactions provide valuable information, they should be part of a broader analysis in making investment decisions.
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Cracking Transaction Codes</h3>
In the domain of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their focus to those taking place in the open market, as meticulously outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001668397">Check Out The Full List Of Medpace Hldgs's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MEDP

Major Update: Cornelius P. McCarthy III At Medpace Hldgs Exercises Options, Realizing $0

In a new SEC filing on May 20, it was revealed that Zander, Board Member at Medpace Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>), executed a significant exercise of company stock options.
What Happened: In an insider options sale disclosed in a Form 4 filing on Tuesday with the <a href="https://www.sec.gov/Archives/edgar/data/0001668397/000166839725000073//Archives/edgar/data/1668397/000166839725000073/0001668397-25-000073-index.htm">U.S. Securities and Exchange Commission</a>, Zander, Board Member at Medpace Hldgs, exercised stock options for 0 shares of MEDP. The transaction value amounted to $0.
Medpace Hldgs shares are trading down 3.26% at $296.62 at the time of this writing on Wednesday morning. Since the current price is $296.62, this makes Zander's 0 shares worth $0.
<h3>About Medpace Hldgs</h3>
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical-device firms. It also offers ancillary services such as bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati and its operations are principally based in the US, but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
<h3>A Deep Dive into Medpace Hldgs's Financials</h3>
Revenue Growth: Over the 3 months period, Medpace Hldgs showcased positive performance, achieving a revenue growth rate of 9.3% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Key Profitability Indicators:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 31.93%, suggesting potential challenges in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Medpace Hldgs's EPS is a standout, portraying a positive bottom-line trend that exceeds the industry average with a current EPS of 3.77.
</li>
</ul>
Debt Management: Medpace Hldgs's debt-to-equity ratio is below the industry average at 0.21, reflecting a lower dependency on debt financing and a more conservative financial approach.
Evaluating Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 23.41, the stock indicates an attractive valuation, potentially presenting a buying opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: The P/S ratio of 4.52 is lower than the industry average, implying a discounted valuation for Medpace Hldgs's stock in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Indicated by a lower-than-industry-average EV/EBITDA ratio of 17.5, the company suggests a potential undervaluation, which might be advantageous for value-focused investors.
</li>
</ul>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Pay Attention to Insider Transactions</h3>
Insightful as they may be, insider transactions should be considered alongside a thorough examination of other investment criteria.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>A Closer Look at Important Transaction Codes</h3>
Examining transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often concentrate on those unfolding in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001668397">Check Out The Full List Of Medpace Hldgs's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Dani S Zander Decides To Exercise Options At Medpace Hldgs Worth $0

Disclosed in a recent SEC filing on May 20, Tarr, President &amp; CEO at Encompass Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EHC#NYSE">EHC</a>), made a noteworthy transaction involving the exercise of company stock options.
What Happened: Disclosed in a Form 4 filing on Tuesday with the <a href="https://www.sec.gov/Archives/edgar/data/0000785161/000112760225015049//Archives/edgar/data/785161/000112760225015049/0001127602-25-015049-index.htm">U.S. Securities and Exchange Commission</a>, Tarr, President &amp; CEO at Encompass Health, executed a strategic derivative sale. This involved exercising stock options for 118,384 shares of EHC, resulting in a transaction value of $9,663,771.
Currently, Encompass Health shares are trading down 0.0%, priced at $121.73 during Wednesday's morning. This values Tarr's 118,384 shares at $9,663,771.
<h3>Get to Know Encompass Health Better</h3>
Encompass Health Corp provides post-acute healthcare services in the United States through a network of inpatient rehabilitation hospitals. Inpatient rehabilitation contributes the majority of the firm's revenue and provides specialized rehabilitative treatment through a network of inpatient hospitals. These hospitals are concentrated in the eastern half of the United States and Texas.
<h3>Financial Insights: Encompass Health</h3>
Revenue Growth: Over the 3 months period, Encompass Health showcased positive performance, achieving a revenue growth rate of 10.59% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Analyzing Profitability Metrics:
<ul>
<li>
Gross Margin: The company issues a cost efficiency warning with a low gross margin of 43.35%, indicating potential difficulties in maintaining profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Encompass Health's EPS is a standout, portraying a positive bottom-line trend that exceeds the industry average with a current EPS of 1.5.
</li>
</ul>
Debt Management: Encompass Health's debt-to-equity ratio is below the industry average at 1.25, reflecting a lower dependency on debt financing and a more conservative financial approach.
Valuation Metrics: A Closer Look
<ul>
<li>
Price to Earnings (P/E) Ratio: Encompass Health's current Price to Earnings (P/E) ratio of 25.05 is higher than the industry average, indicating that the stock may be overvalued according to market sentiment.
</li>
<li>
Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 2.26 as compared to the industry average, the stock might be considered overvalued based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an impressive EV/EBITDA ratio of 11.88, Encompass Health demonstrates exemplary market valuation, surpassing industry averages.
</li>
</ul>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Illuminating the Importance of Insider Transactions</h3>
Insider transactions should be considered alongside other factors when making investment decisions, as they can offer important insights.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Deciphering Transaction Codes in Insider Filings</h3>
Delving into transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> typically prioritize those unfolding in the open market, as precisely outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000785161">Check Out The Full List Of Encompass Health's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

President & CEO At Encompass Health Exercises Options Worth $9.66M

A notable acquisition unfolded on May 20, as Huss, Board Member at InfuSystems Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INFU#AMEX">INFU</a>), reported the acquisition of stock options for 39,588 shares in an SEC filing.
What Happened: Uncovered in a Form 4 filing on Tuesday with the <a href="https://www.sec.gov/Archives/edgar/data/0001337013/000162828025026948//Archives/edgar/data/1337013/000162828025026948/0001628280-25-026948-index.htm">U.S. Securities and Exchange Commission</a>, Huss, Board Member at InfuSystems Holdings, executed an insider options move. This move consisted of acquiring stock options for 39,588 shares of INFU, granting Huss the right to purchase the company's stock at an exercise price of $6.0 per share.
InfuSystems Holdings shares are currently trading down by 1.23%, with a current price of $6.03 as of Wednesday morning. This brings the total value of Huss's 39,588 shares to $989.
<h3>Discovering InfuSystems Holdings: A Closer Look</h3>
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-reportable segment. The first is Patient Services, providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The Patient segment is comprised of Oncology, Pain Management and Wound Therapy businesses. The second, Device Solutions, supports the Patient Services platform and leverages service orientation to win incremental business from its direct payer clients. The Device segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair. Majority from Patient.
<h3>InfuSystems Holdings: A Financial Overview</h3>
Positive Revenue Trend: Examining InfuSystems Holdings's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 8.5% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: Achieving a high gross margin of 55.21%, the company performs well in terms of cost management and profitability within its sector.
</li>
<li>
Earnings per Share (EPS): InfuSystems Holdings's EPS reflects a decline, falling below the industry average with a current EPS of -0.01.
</li>
</ul>
Debt Management: InfuSystems Holdings's debt-to-equity ratio surpasses industry norms, standing at 0.6. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
Insights into Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 40.67, the stock indicates an attractive valuation, potentially presenting a buying opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: With a lower-than-average P/S ratio of 0.96, the stock presents an attractive valuation, potentially signaling a buying opportunity for investors interested in sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): InfuSystems Holdings's EV/EBITDA ratio, lower than industry averages at 7.53, indicates attractively priced shares.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Illuminating the Importance of Insider Transactions</h3>
Insider transactions are not the sole determinant of investment choices, but they are a factor worth considering.
In the realm of legality, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities under Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are required to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Notably, when a company insider makes a new purchase, it is considered an indicator of their positive expectations for the stock.
Conversely, insider sells may not necessarily signal a bearish stance on the stock and can be motivated by various factors.
<h3>Important Transaction Codes</h3>
For <a href="https://www.benzinga.com/money/investing-tools">investors</a>, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001337013">Check Out The Full List Of InfuSystems Holdings's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

INFU

Smart Decision: Beverly A Huss Acquires InfuSystems Holdings Stock Options Worth $989

Thermon Group Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THR#NYSE">THR</a>) is set to give its latest quarterly earnings report on Thursday, 2025-05-22. Here's what investors need to know before the announcement.
Analysts estimate that Thermon Group Holdings will report an earnings per share (EPS) of $0.50. 
Anticipation surrounds Thermon Group Holdings's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Overview of Past Earnings</h3>
In the previous earnings release, the company beat EPS by $0.01, leading to a 3.77% increase in the share price the following trading session.
Here's a look at Thermon Group Holdings's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2025</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.55</td>
<td>0.37</td>
<td>0.31</td>
<td>0.32</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.56</td>
<td>0.38</td>
<td>0.38</td>
<td>0.34</td>
</tr>
<tr>
<td>Price Change %</td>
<td>4.0%</td>
<td>-2.0%</td>
<td>-0.0%</td>
<td>3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747839742_0.png" alt="eps graph" />
<h3>Thermon Group Holdings Share Price Analysis</h3>
Shares of Thermon Group Holdings were trading at $29.7 as of May 20. Over the last 52-week period, shares are down 15.88%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/THR/earnings">To track all earnings releases for Thermon Group Holdings visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Insights Ahead: Thermon Group Holdings's Quarterly Earnings

Scott Shuda, Board Member at InfuSystems Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INFU#AMEX">INFU</a>), reported acquisition of company stock options on May 20, according to a new SEC filing.
What Happened: Disclosed in a Form 4 filing on Tuesday with the <a href="https://www.sec.gov/Archives/edgar/data/0001337013/000162828025026951//Archives/edgar/data/1337013/000162828025026951/0001628280-25-026951-index.htm">U.S. Securities and Exchange Commission</a>, Shuda, Board Member at InfuSystems Holdings, made a strategic derivative acquisition. This involved acquiring stock options for 51,464 shares of INFU, providing the right to buy the company's stock at an exercise price of $6.0 per share.
During Wednesday's morning session, InfuSystems Holdings shares down by 1.23%, currently priced at $6.03. Considering the current price, Shuda's 51,464 shares have a total value of $1,286.
<h3>About InfuSystems Holdings</h3>
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-reportable segment. The first is Patient Services, providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The Patient segment is comprised of Oncology, Pain Management and Wound Therapy businesses. The second, Device Solutions, supports the Patient Services platform and leverages service orientation to win incremental business from its direct payer clients. The Device segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair. Majority from Patient.
<h3>InfuSystems Holdings's Economic Impact: An Analysis</h3>
Revenue Growth: InfuSystems Holdings's remarkable performance in 3 months is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 8.5%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Exploring Profitability:
<ul>
<li>
Gross Margin: With a high gross margin of 55.21%, the company demonstrates effective cost control and strong profitability relative to its peers.
</li>
<li>
Earnings per Share (EPS): InfuSystems Holdings's EPS lags behind the industry average, indicating concerns and potential challenges with a current EPS of -0.01.
</li>
</ul>
Debt Management: InfuSystems Holdings's debt-to-equity ratio stands notably higher than the industry average, reaching 0.6. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
In-Depth Valuation Examination:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 40.67, the stock indicates an attractive valuation, potentially presenting a buying opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: The P/S ratio of 0.96 is lower than the industry average, implying a discounted valuation for InfuSystems Holdings's stock in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With a lower-than-industry-average EV/EBITDA ratio of 7.53, InfuSystems Holdings presents a potential value opportunity, as investors are paying less for each unit of EBITDA.
</li>
</ul>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Pay Attention to Insider Transactions</h3>
While insider transactions provide valuable information, they should be part of a broader analysis in making investment decisions.
From a legal standpoint, the term "insider" pertains to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
A company insider's new purchase is a indicator of their positive anticipation for a rise in the stock.
While insider sells may not necessarily reflect a bearish view and can be motivated by various factors.
<h3>Transaction Codes To Focus On</h3>
Examining transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often concentrate on those unfolding in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001337013">Check Out The Full List Of InfuSystems Holdings's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Scott Shuda Expands Holdings With InfuSystems Holdings Stock Options Worth $1K

A substantial insider move unfolded on May 20, as Hundzinski, Director at InfuSystems Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INFU#AMEX">INFU</a>), reported the acquisition of stock options for 39,588 shares in an SEC filing.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0001337013/000162828025026953//Archives/edgar/data/1337013/000162828025026953/0001628280-25-026953-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday showed that Hundzinski, Director at InfuSystems Holdings, a company in the Health Care sector, acquired stock options for 39,588 shares of INFU. The options allow Hundzinski to buy the company's stock at $6.0 per share.
The Wednesday morning market activity shows InfuSystems Holdings shares down by 1.23%, trading at $6.03. This implies a total value of $989 for Hundzinski's 39,588 shares.
<h3>About InfuSystems Holdings</h3>
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-reportable segment. The first is Patient Services, providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The Patient segment is comprised of Oncology, Pain Management and Wound Therapy businesses. The second, Device Solutions, supports the Patient Services platform and leverages service orientation to win incremental business from its direct payer clients. The Device segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair. Majority from Patient.
<h3>A Deep Dive into InfuSystems Holdings's Financials</h3>
Revenue Growth: Over the 3 months period, InfuSystems Holdings showcased positive performance, achieving a revenue growth rate of 8.5% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Profitability Metrics:
<ul>
<li>
Gross Margin: Achieving a high gross margin of 55.21%, the company performs well in terms of cost management and profitability within its sector.
</li>
<li>
Earnings per Share (EPS): InfuSystems Holdings's EPS reflects a decline, falling below the industry average with a current EPS of -0.01.
</li>
</ul>
Debt Management: InfuSystems Holdings's debt-to-equity ratio stands notably higher than the industry average, reaching 0.6. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
Valuation Metrics: A Closer Look
<ul>
<li>
Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 40.67, the stock indicates an attractive valuation, potentially presenting a buying opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: The P/S ratio of 0.96 is lower than the industry average, implying a discounted valuation for InfuSystems Holdings's stock in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): InfuSystems Holdings's EV/EBITDA ratio at 7.53 suggests potential undervaluation, falling below industry averages.
</li>
</ul>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Activity Matters in Finance</h3>
It's important to note that insider transactions alone should not dictate investment decisions, but they can provide valuable insights.
In the realm of legality, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities under Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are required to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Notably, when a company insider makes a new purchase, it is considered an indicator of their positive expectations for the stock.
Conversely, insider sells may not necessarily signal a bearish stance on the stock and can be motivated by various factors.
<h3>Transaction Codes To Focus On</h3>
In the domain of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their focus to those taking place in the open market, as meticulously outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001337013">Check Out The Full List Of InfuSystems Holdings's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Smart Decision: Ronald T Hundzinski Acquires InfuSystems Holdings Stock Options Worth $989

Dorian LPG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPG#NYSE">LPG</a>) is set to give its latest quarterly earnings report on Thursday, 2025-05-22. Here's what investors need to know before the announcement.
Analysts estimate that Dorian LPG will report an earnings per share (EPS) of $0.49. 
Anticipation surrounds Dorian LPG's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Performance in Previous Earnings</h3>
In the previous earnings release, the company missed EPS by $0.18, leading to a 0.0% drop in the share price the following trading session.
Here's a look at Dorian LPG's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2025</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.61</td>
<td>0.56</td>
<td>0.88</td>
<td>1.83</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.43</td>
<td>0.35</td>
<td>1.26</td>
<td>1.91</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-5.0%</td>
<td>2.0%</td>
<td>-4.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747839733_0.png" alt="eps graph" />
<h3>Performance of Dorian LPG Shares</h3>
Shares of Dorian LPG were trading at $23.41 as of May 20. Over the last 52-week period, shares are down 49.45%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/LPG/earnings">To track all earnings releases for Dorian LPG visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What to Expect from Dorian LPG's Earnings

A substantial acquisition of company stock options by Paul A. Gendron, Director at InfuSystems Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INFU#AMEX">INFU</a>) was reported on May 20, based on a new SEC filing.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0001337013/000162828025026954//Archives/edgar/data/1337013/000162828025026954/0001628280-25-026954-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday showed that Gendron, Director at InfuSystems Holdings, a company in the Health Care sector, acquired stock options for 39,588 shares of INFU. The options allow Gendron to buy the company's stock at $6.0 per share.
InfuSystems Holdings shares are trading, exhibiting down of 1.23% and priced at $6.03 during Wednesday's morning. This values Gendron's 39,588 shares at $989.
<h3>Discovering InfuSystems Holdings: A Closer Look</h3>
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-reportable segment. The first is Patient Services, providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The Patient segment is comprised of Oncology, Pain Management and Wound Therapy businesses. The second, Device Solutions, supports the Patient Services platform and leverages service orientation to win incremental business from its direct payer clients. The Device segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair. Majority from Patient.
<h3>Breaking Down InfuSystems Holdings's Financial Performance</h3>
Revenue Growth: InfuSystems Holdings's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 8.5%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Evaluating Earnings Performance:
<ul>
<li>
Gross Margin: Achieving a high gross margin of 55.21%, the company performs well in terms of cost management and profitability within its sector.
</li>
<li>
Earnings per Share (EPS): InfuSystems Holdings's EPS is below the industry average. The company faced challenges with a current EPS of -0.01. This suggests a potential decline in earnings.
</li>
</ul>
Debt Management: InfuSystems Holdings's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.6, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
Understanding Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: InfuSystems Holdings's P/E ratio of 40.67 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: The Price to Sales ratio is 0.96, which is lower than the industry average. This suggests a possible undervaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio of 7.53 trails industry averages, indicating a potential disparity in market valuation that could be advantageous for investors.
</li>
</ul>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Navigating the Impact of Insider Transactions on Investments</h3>
Emphasizing the importance of a comprehensive approach, considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
In the realm of legality, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities under Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are required to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Notably, when a company insider makes a new purchase, it is considered an indicator of their positive expectations for the stock.
Conversely, insider sells may not necessarily signal a bearish stance on the stock and can be motivated by various factors.
<h3>Essential Transaction Codes Unveiled</h3>
In the domain of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their focus to those taking place in the open market, as meticulously outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001337013">Check Out The Full List Of InfuSystems Holdings's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Smart Decision: Paul A. Gendron Acquires InfuSystems Holdings Stock Options Worth $989

Lionsgate Studios (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LION#NASDAQ">LION</a>) is set to give its latest quarterly earnings report on Thursday, 2025-05-22. Here's what investors need to know before the announcement.
Analysts estimate that Lionsgate Studios will report an earnings per share (EPS) of $0.41. 
Anticipation surrounds Lionsgate Studios's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings Track Record</h3>
The company's EPS beat by $0.25 in the last quarter, leading to a 14.5% increase in the share price on the following day.
Here's a look at Lionsgate Studios's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2025</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.03</td>
<td>-0.24</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.28</td>
<td>-0.43</td>
<td>0.09</td>
<td>0.27</td>
</tr>
<tr>
<td>Price Change %</td>
<td>14.000000000000002%</td>
<td>3.0%</td>
<td>-1.0%</td>
<td>-9.0%</td>
</tr>
</tbody>
</table>

<h3>Performance of Lionsgate Studios Shares</h3>
Shares of Lionsgate Studios were trading at $7.06 as of May 20. Over the last 52-week period, shares are down 27.72%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/LION/earnings">To track all earnings releases for Lionsgate Studios visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LION

Earnings Preview For Lionsgate Studios

A notable acquisition unfolded on May 20, as Eichenbaum, Board Member at InfuSystems Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INFU#AMEX">INFU</a>), reported the acquisition of stock options for 39,588 shares in an SEC filing.
What Happened: Uncovered in a Form 4 filing on Tuesday with the <a href="https://www.sec.gov/Archives/edgar/data/0001337013/000162828025026958//Archives/edgar/data/1337013/000162828025026958/0001628280-25-026958-index.htm">U.S. Securities and Exchange Commission</a>, Eichenbaum, Board Member at InfuSystems Holdings, executed an insider options move. This move consisted of acquiring stock options for 39,588 shares of INFU, granting Eichenbaum the right to purchase the company's stock at an exercise price of $6.0 per share.
During Wednesday's morning session, InfuSystems Holdings shares down by 1.23%, currently priced at $6.03. Considering the current price, Eichenbaum's 39,588 shares have a total value of $989.
<h3>Get to Know InfuSystems Holdings Better</h3>
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-reportable segment. The first is Patient Services, providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The Patient segment is comprised of Oncology, Pain Management and Wound Therapy businesses. The second, Device Solutions, supports the Patient Services platform and leverages service orientation to win incremental business from its direct payer clients. The Device segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair. Majority from Patient.
<h3>InfuSystems Holdings's Economic Impact: An Analysis</h3>
Revenue Growth: InfuSystems Holdings's remarkable performance in 3 months is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 8.5%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Evaluating Earnings Performance:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 55.21%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): With an EPS below industry norms, InfuSystems Holdings exhibits below-average bottom-line performance with a current EPS of -0.01.
</li>
</ul>
Debt Management: InfuSystems Holdings's debt-to-equity ratio stands notably higher than the industry average, reaching 0.6. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
Evaluating Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 40.67 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: With a P/S ratio of 0.96 below industry standards, the stock shows potential undervaluation, making it an appealing investment option for those focusing on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Indicated by a lower-than-industry-average EV/EBITDA ratio of 7.53, the company suggests a potential undervaluation, which might be advantageous for value-focused investors.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Understanding the Significance of Insider Transactions</h3>
It's important to note that insider transactions alone should not dictate investment decisions, but they can provide valuable insights.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Important Transaction Codes</h3>
When analyzing transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase,while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001337013">Check Out The Full List Of InfuSystems Holdings's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

In A Strategic Move, Kenneth D Eichenbaum Acquires InfuSystems Holdings Stock Options Worth $989: Enhancing Value

Highlighted on May 20, it was unveiled in an SEC filing that LeMaitre, Chairman and CEO at LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>), executed a significant transaction involving the exercise of company stock options.
What Happened: LeMaitre, Chairman and CEO at LeMaitre Vascular, exercised stock options for 34,619 shares of LMAT stock. This information was disclosed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001158895/000143774925017883//Archives/edgar/data/1158895/000143774925017883/0001437749-25-017883-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday. The exercise price of the options was $44.64 per share.
During Wednesday's morning session, LeMaitre Vascular shares down by 0.0%, currently priced at $84.75. Considering the current price, LeMaitre's 34,619 shares have a total value of $1,388,667.
<h3>Delving into LeMaitre Vascular's Background</h3>
LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches and vessel closure systems.It has a single operating segment engaged in the development, manufacturing, and marketing of medical devices and implants, as well as the processing and cryopreservation of human tissues for implantation in patients.
<h3>Breaking Down LeMaitre Vascular's Financial Performance</h3>
Revenue Growth: LeMaitre Vascular displayed positive results in 3 months. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 11.95%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Holistic Profitability Examination:
<ul>
<li>
Gross Margin: With a high gross margin of 69.18%, the company demonstrates effective cost control and strong profitability relative to its peers.
</li>
<li>
Earnings per Share (EPS): The company excels with an EPS that surpasses the industry average. With a current EPS of 0.49, LeMaitre Vascular showcases strong earnings per share.
</li>
</ul>
Debt Management: LeMaitre Vascular's debt-to-equity ratio is below the industry average. With a ratio of 0.53, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Exploring Valuation Metrics Landscape:
<ul>
<li>
Price to Earnings (P/E) Ratio: LeMaitre Vascular's P/E ratio of 43.02 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 8.56 as compared to the industry average, the stock might be considered overvalued based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): At 25.81, the company's EV/EBITDA ratio outperforms industry norms, reflecting positive market perception. This positioning indicates optimistic expectations for the company's future performance.
</li>
</ul>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Impact of Insider Transactions on Investments</h3>
Investors should view insider transactions as part of a multifaceted analysis and not rely solely on them for decision-making.
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Important Transaction Codes</h3>
Navigating through the landscape of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, precisely detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001158895">Check Out The Full List Of LeMaitre Vascular's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LMAT

Insider Move: George LeMaitre Exercises Options, Realizing $1.39M At LeMaitre Vascular

Titan Machinery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TITN#NASDAQ">TITN</a>) is preparing to release its quarterly earnings on Thursday, 2025-05-22. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Titan Machinery to report an earnings per share (EPS) of $-0.88.
The announcement from Titan Machinery is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Earnings History Snapshot</h3>
In the previous earnings release, the company missed EPS by $1.26, leading to a 2.5% increase in the share price the following trading session.
Here's a look at Titan Machinery's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2025</th>
<th>Q3 2025</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.62</td>
<td>0.05</td>
<td>0.19</td>
<td>0.64</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.88</td>
<td>0.07</td>
<td>0.17</td>
<td>0.41</td>
</tr>
<tr>
<td>Price Change %</td>
<td>2.0%</td>
<td>-2.0%</td>
<td>6.0%</td>
<td>-6.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747839717_0.png" alt="eps graph" />
<h3>Titan Machinery Share Price Analysis</h3>
Shares of Titan Machinery were trading at $20.63 as of May 20. Over the last 52-week period, shares are up 4.03%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<h3>Analyst Observations about Titan Machinery</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Titan Machinery.
A total of 2 analyst ratings have been received for Titan Machinery, with the consensus rating being Outperform. The average one-year price target stands at $24.5, suggesting a potential 18.76% upside.
<h3>Peer Ratings Overview</h3>
In this comparison, we explore the analyst ratings and average 1-year price targets of and Titan Machinery, three prominent industry players, offering insights into their relative performance expectations and market positioning.
<h3>Comprehensive Peer Analysis Summary</h3>
Within the peer analysis summary, vital metrics for and Titan Machinery are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Titan Machinery</td>
<td>Outperform</td>
<td>-10.82%</td>
<td>$51.00M</td>
<td>-6.81%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Titan Machinery is at the bottom for Revenue Growth, with a decrease of 10.82%. It also ranks lowest for Gross Profit at $51.00M. Additionally, it has the lowest Return on Equity at -6.81%. Overall, Titan Machinery is performing less favorably compared to its peers in these key metrics.
<h3>Discovering Titan Machinery: A Closer Look</h3>
Titan Machinery Inc owns and operates a network of full-service agricultural and construction equipment stores. The company sells and repairs agricultural equipment, including machinery and attachments for large-scale farming and home and gardening purposes, as well as construction equipment. It operates through the following segments: The Agriculture segment sells, services, and rents machinery and related parts and attachments, for uses ranging from large-scale farming to home and garden use, The construction segment sells, services, and rents machinery, and related parts and attachments, for uses ranging from heavy construction to light industrial machinery use, and the Europe and Australia segments.
<h3>Titan Machinery's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Titan Machinery's revenue growth over a period of 3 months has faced challenges. As of 31 January, 2025, the company experienced a revenue decline of approximately -10.82%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.
Net Margin: Titan Machinery's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -5.74%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Titan Machinery's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -6.81%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -2.22%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Titan Machinery's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.63.
<a href="https://www.benzinga.com/quote/TITN/earnings">To track all earnings releases for Titan Machinery visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TITN

A Look Ahead: Titan Machinery's Earnings Forecast

Highlighted on May 21, it was unveiled in an SEC filing that Diefenbach, SVP at Ethan Allen Interiors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETD#NYSE">ETD</a>), executed a significant transaction involving the exercise of company stock options.
What Happened: In an insider options sale disclosed in a Form 4 filing on Wednesday with the <a href="https://www.sec.gov/Archives/edgar/data/0000896156/000143774925017889//Archives/edgar/data/896156/000143774925017889/0001437749-25-017889-index.htm">U.S. Securities and Exchange Commission</a>, Diefenbach, SVP at Ethan Allen Interiors, exercised stock options for 666 shares of ETD. The transaction value amounted to $685.
As of Wednesday morning, Ethan Allen Interiors shares are down by 0.0%, with a current price of $27.22. This implies that Diefenbach's 666 shares have a value of $685.
<h3>Delving into Ethan Allen Interiors's Background</h3>
Ethan Allen Interiors Inc through its subsidiaries, operates as an interior design company, and a manufacturer and retailer in the home furnishings marketplace. Its product offerings include fabric chairs, beds, wallpapers, desks, and dining tables among others. The company's reportable segments are; Wholesale and Retail. The Wholesale segment is principally involved in the development of the Ethan Allen brand and encompasses all aspects of design, manufacturing, sourcing, marketing, sale, and distribution of home furnishings and accents. The Retail segment which generates maximum revenue, sells home furnishings and accents to clients through company-operated design centers. Geographically, it derives key revenue from the United States and the rest from other regions.
<h3>Ethan Allen Interiors: A Financial Overview</h3>
Negative Revenue Trend: Examining Ethan Allen Interiors's financials over 3 months reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately -2.54% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Interpreting Earnings Metrics:
<ul>
<li>
Gross Margin: The company maintains a high gross margin of 61.22%, indicating strong cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Ethan Allen Interiors's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of 0.38.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 0.26, Ethan Allen Interiors adopts a prudent financial strategy, indicating a balanced approach to debt management.
Exploring Valuation Metrics Landscape:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 12.1, the stock indicates an attractive valuation, potentially presenting a buying opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 1.12 is above industry norms, reflecting an elevated valuation for Ethan Allen Interiors's stock and potential overvaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Indicated by a lower-than-industry-average EV/EBITDA ratio of 6.91, the company suggests a potential undervaluation, which might be advantageous for value-focused investors.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Key in Investment Decisions</h3>
While insider transactions should not be the sole basis for making investment decisions, they can play a significant role in an investor's decision-making process.
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>The Insider's Guide to Important Transaction Codes</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates grant, award or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000896156">Check Out The Full List Of Ethan Allen Interiors's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Engaging In Insider Activity, Douglas H Diefenbach At Ethan Allen Interiors Exercises Options Worth $685

Advance Auto Parts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>) is preparing to release its quarterly earnings on Thursday, 2025-05-22. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Advance Auto Parts to report an earnings per share (EPS) of $-0.62.
Anticipation surrounds Advance Auto Parts's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings History Snapshot</h3>
During the last quarter, the company reported an EPS missed by $0.00, leading to a 1.96% drop in the share price on the subsequent day.
Here's a look at Advance Auto Parts's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.18</td>
<td>0.54</td>
<td>0.95</td>
<td>0.68</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.18</td>
<td>-0.04</td>
<td>0.75</td>
<td>0.67</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-2.0%</td>
<td>-9.0%</td>
<td>-4.0%</td>
<td>7.000000000000001%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747839707_0.png" alt="eps graph" />
<h3>Performance of Advance Auto Parts Shares</h3>
Shares of Advance Auto Parts were trading at $34.16 as of May 20. Over the last 52-week period, shares are down 53.4%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Analyst Views on Advance Auto Parts</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Advance Auto Parts.
The consensus rating for Advance Auto Parts is Neutral, derived from 8 analyst ratings. An average one-year price target of $41.25 implies a potential 20.76% upside.
<h3>Peer Ratings Comparison</h3>
In this analysis, we delve into the analyst ratings and average 1-year price targets of Sonic Automotive and Camping World Holdings, three key industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Sonic Automotive, with an average 1-year price target of $74.0, suggesting a potential 116.63% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Camping World Holdings, with an average 1-year price target of $18.43, suggesting a potential 46.05% downside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
The peer analysis summary presents essential metrics for Sonic Automotive and Camping World Holdings, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advance Auto Parts</td>
<td>Neutral</td>
<td>-0.91%</td>
<td>$347.12M</td>
<td>-17.40%</td>
</tr>
<tr>
<td>Sonic Automotive</td>
<td>Buy</td>
<td>7.90%</td>
<td>$566.40M</td>
<td>6.56%</td>
</tr>
<tr>
<td>Camping World Holdings</td>
<td>Outperform</td>
<td>3.63%</td>
<td>$429.63M</td>
<td>-3.86%</td>
</tr>
</tbody>
</table>

Key Takeaway:
In terms of consensus rating, Advance Auto Parts is rated lower than one peer and higher than another. For revenue growth, it is at the bottom compared to its peers. Regarding gross profit, it is also at the bottom among the group. Lastly, for return on equity, Advance Auto Parts is positioned at the bottom compared to the other companies.
<h3>All You Need to Know About Advance Auto Parts</h3>
Advance Auto Parts is a leading auto-parts retailer in North America with more than 4,000 store and branch locations. About 50% of the firm's sales are geared toward the professional channel, with the remaining sales in the do-it-yourself market. Through its vast store footprint and distribution network, Advance manages thousands of stock-keeping units for various vehicle makes and models. The retailer primarily competes on the basis of inventory availability and service speed, making the operating efficiency of its hub-and-spoke distribution model critical to meeting customer needs.
<h3>Breaking Down Advance Auto Parts's Financial Performance</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Negative Revenue Trend: Examining Advance Auto Parts's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -0.91% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Advance Auto Parts's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -20.78%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Advance Auto Parts's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -17.4%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -3.57%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Advance Auto Parts's debt-to-equity ratio is below the industry average. With a ratio of 1.7, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/AAP/earnings">To track all earnings releases for Advance Auto Parts visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Wheaton Precious Metals

Noticias

Últimas noticias sobre Wheaton Precious Metals (NYSE:WPM) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL